赞努布鲁丁尼布在地幔细胞淋巴瘤管理中的应用:综合性审查
Nada Alsuhebany1,2,3, Congshan Pan4, Eileen Holovac5
1College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia.
Blood and lymphatic cancer : targets and therapy
|November 30, 2023
概括
尚布鲁丁尼布是一种布鲁顿的氨酸激酶抑制剂 (BTKI),在治疗复发性/耐药性地幔细胞淋巴瘤 (MCL) 中表现出显著的疗效. 这种向治疗为MCL患者提供了改善的生存结果和有利的安全概况.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 膜细胞淋巴瘤 (MCL) 是一种侵略性的B细胞非霍奇金淋巴瘤 (NHL),在复发/耐药 (R/R) 环境中表现不佳.
- 治疗的进步包括免疫疗法和向疗法,改变了MCL管理.
- 赞努布鲁丁尼布是一种第二代布鲁顿的氨酸激酶抑制剂 (BTKI),向成熟的B细胞恶性瘤.
研究的目的:
- 描述扎努布鲁丁尼布的药理学,药理动力学,药理动力学,临床疗效和安全性.
- 评估扎努布鲁丁尼布在治疗复发性/耐药性MCL患者中的作用.
主要方法:
- 临床前研究表明,扎努布鲁丁尼布可以抑制恶性B细胞增殖和瘤生长.
- 第一期和第二期临床试验评估了扎努布鲁丁尼布在R/RMCL中的疗效和安全性.
- 赞努布鲁丁尼布作为一种不可逆转的BTK抑制剂,对B细胞受体信号传递至关重要.
主要成果:
- 赞努布鲁丁尼布在R/RMCL患者中显示了83.7%的整体应答率,其中78%的患者实现了完全应答.
- 响应的中位持续时间为19.5个月,中位无进展生存时间为22.1个月.
- 常见的不良事件 (≥20%) 包括中性质衰竭,上呼吸道感染,皮疹,白血病和血小板衰竭.
结论:
- 赞努布鲁丁尼布是一种选择性,口服活性,不可逆转的BTK抑制剂.
- 它的疗效和耐受性良好的安全性使其成为R/R MCL的有吸引力的选择.
- 赞努布鲁丁尼布显著改善了复发性/耐药性MCL患者的生存结果.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K